What is the difference between Cerebrolysin and VIP?

Cerebrolysin: Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity VIP: Pleiotropic neuropeptide binding VPAC1/VPAC2 receptors; suppresses neuroinflammation, regulates circadian rhythm via SCN, modulates immune response

Is Cerebrolysin FDA approved?

Cerebrolysin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

VIP is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Cerebrolysin administered in research settings?

In research settings, Cerebrolysin is typically administered via the intravenous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

How is VIP administered in research settings?

In research settings, VIP is typically administered via the intranasal or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Cerebrolysin vs VIP

Peptide Comparison

Cerebrolysin vs VIP

Name: Cerebrolysin vs VIP — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Neuro & Cognitive peptides.

Cerebrolysin

FPF 1070

CognitiveInvestigationalResearch Only

Half-life: Varies by component

32 providers listed

Full Cerebrolysin profile →

VIP

Vasoactive Intestinal Peptide

CognitiveNot EvaluatedResearch Only

Half-life: ~1-2 minutes (plasma)

22 providers listed

Full VIP profile →

Bottom line

Cerebrolysin carries stronger published evidence (Meta-analysis, 5 key studies) than VIP (Review, 2); both are research compounds.

Quick Verdict

Cerebrolysin

Evidence

Established Clinical

Half-life

Varies by component

VIP

Evidence

Preclinical

Half-life

~1-2 minutes (plasma)

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Cerebrolysin
Further along in FDA review	Cerebrolysin
Lower typical price per mg	Cerebrolysin
More provider options (32 vs 22)	Cerebrolysin

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Cerebrolysin

VIP

Mechanism Family

Neuro & Cognitive

Half-life

Varies by component

~1-2 minutes (plasma)

FDA Status

investigational

not evaluated

Admin Routes

intravenous, intramuscular

intranasal, intravenous

Availability

Research Only

Providers

32 listed

22 listed

Avail. Notes

Neuropeptide mixture approved in EU/Asia but NOT FDA-approved. Phase 2/3 US trials for Alzheimer's disease and stroke with active IND. No NDA filed. Research use in US.

Endogenous 28-aa neuropeptide. No FDA-approved product. Inhaled VIP studied in Phase 2 for pulmonary arterial hypertension (Santhera); program not advanced. No NDA filed. Research use only.

Research Evidence

Cerebrolysin

Established ClinicalMeta-analysis · 5 key studies · most recent 2026

VIP

PreclinicalReview · 2 key studies · most recent 2022

Research Citations

Cerebrolysin

Cohort2026 · Cells

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothel…

Cohort2026 · Biomolecules

Biochemical and Pharmacological Studies on Kynurenic Acid Metabolism in the Helix pomatia-Snail Model of Lear…

Cohort2026 · Asian J Neurosurg

Neuroprotective Effects of Cerebrolysin in Moderate Traumatic Brain Injury with Nonoperative Lesions: A 6-Mon…

RCT2024 · Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Cerebrolysin in the preventive therapy of dementia in elderly patients with mild cognitive impairment: a thre…

+1 more

VIP

In vitro2022 · Journal of Molecular Neuroscience

PACAP and VIP Mitigate Rotenone-Induced Inflammation in BV-2 Microglial Cells

Review2017 · Mediators of Inflammation

Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases

About Cerebrolysin

Standardized mixture of neuropeptides derived from porcine brain proteins; mimics endogenous neurotrophic factors (BDNF, NGF, CNTF); promotes neurogenesis and synaptic plasticity

Research Areas

neuroprotectionneuroplasticitymemory improvementcognitive recovery

About VIP

Pleiotropic neuropeptide binding VPAC1/VPAC2 receptors; suppresses neuroinflammation, regulates circadian rhythm via SCN, modulates immune response

Research Areas

neuroprotectionanti-inflammatory (CNS)CIRS treatmentcircadian rhythm regulation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Cerebrolysin

Reported (Unverified — Pending Clinical Review)

epilepsyrenal failureporcine protein allergy

No established clinical contraindications

VIP

Reported (Unverified — Pending Clinical Review)

low blood pressurevasoactive drug interactions

No established clinical contraindications

Price (per mg)

Cerebrolysin

$1.12/mg

$1.05 – $1.78 range

6 vendors

View price index →Find providers →

VIP

$5.50/mg

$4.00 – $8.00 range

9 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

Cerebrolysin

32 listed

Browse directory →

Providers offering

VIP

22 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Neuro & Cognitive Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 20, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Cerebrolysin vs VIP — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cerebrolysin/vip

https://peptidebase.io/peptides/compare/cerebrolysin/vip Methodology License Download JSON Download CSV